拓扑异构酶Ⅱ在化疗后患者骨肉瘤组织中的表达及其意义  

Expression of Topo Ⅱ in osteosarcoma after chemotherapy and its significance

作　　者：卫江华[1] 郑绘霞[1] 齐寰宇[1] 梁智中[1] 张俊伟[1] 

机构地区：[1]山西省肿瘤医院骨科,太原030013

出　　处：《肿瘤研究与临床》2014年第10期689-690,694,共3页Cancer Research and Clinic

摘　　要：目的 探讨DNA拓扑异构酶Ⅱ（TopoⅡ）在化疗后患者骨肉瘤组织中的表达.方法 对30例骨肉瘤患者术前进行2个疗程化疗,手术切除肿瘤组织,通过免疫组织化学法检测骨肉瘤组织中TopoⅡ的表达,分析其与临床病理因素的关系.结果 30例骨肉瘤组织中TopoⅡ阳性表达8例（26.7％）.TopoⅡ蛋白表达与患者的年龄、性别、肿瘤的恶性程度、发生部位、有无转移及Enneking分期均无关（P＞0.05）,21例生存患者中,TopoⅡ蛋白阴性18例,9例死亡患者中,TopoⅡ蛋白阴性4例,二者阴性表达率差异有统计学意义（P＜0.05）.结论 TopoⅡ低表达的骨肉瘤患者可能预后较差.Objective To probe into the content of DNA Topo Ⅱ in osteosarcoma after chemotherapy.Methods 30 patients with osteosarcoma received two courses of chemotherapy treatment before the surgical resection of the tumor tissue.Then immunohistochemistry was used to detect the content of Topo Ⅱ in tissues and detected its relationship in pathology.Results There were 8 out of 30 cases in which Topo Ⅱ was presented positive in osteosarcoma （26.7 %）.The protein content of Topo Ⅱ was unrelated to the patient＆#39; s age,gender,degree of tumor malignancy,tumor location and translocation or Enneking staging （P 〉 0.05）,but related to patients survival rate （P 〈 0.05）.Conclusion Patients with lower expression of Topo Ⅱ are more likely to have poor prognosis.

关 键 词：骨肉瘤 DNA拓扑异构酶类 Ⅱ型 肿瘤转移 抗药性 肿瘤 预后 

分 类 号：R738.1[医药卫生—肿瘤]